Sun Pharma eyes growth in emerging markets; Merck to shutter Inspire's NC headquarters;

@FiercePharma: Will Abbott's Niaspan fall short of blockbuster sales? Article | Follow @FiercePharma

> India's Sun Pharmaceutical Industries is betting on emerging markets to help sustain its growth momentum, seeking opportunities beyond its traditional U.S. market, where benefits from the current wave of patent expirations are expected to wane after 2015. Article

> Inspire Pharmaceuticals will be eliminating 51 jobs and closing its Raleigh, NC, headquarters Aug. 31 after completing the sale of the company to pharmaceutical giant Merck. Report

> Two senior executives who spearheaded the Asian growth plans of Merck have vacated their positions. Item

> Merck spent $3.56 million lobbying the federal government in the first quarter, on rebates for prescription drug spending, free trade agreements and various tax-related issues, according to a quarterly disclosure report. Report

Pharma News

@FierceBiotech: Lilly outlines turnaround strategy as CEO calls research cuts "nuts." Story | Follow @FierceBiotech

@JohnCFierce: Here's the PR on Acorda's acquisition of Ph2 drug. This biotech knows something about locomotor function. Smart. Item | Follow @JohnCFierce

> Vivus submits NDA for ED drug. Item

> Acorda snags Ph2 neurological trauma program in $35M deal. Story

> AcelRx gets $20M loan for Phase III work. Piece

> Analysis: Biotechs raised record amount of funds in 2010. Report

And Finally... People who are nearsighted may be nearly twice as likely to also develop glaucoma, a leading cause of blindness, according to a study. Story